keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma stage system

keyword
https://www.readbyqxmd.com/read/29338271/analytical-anthropometric-and-dietary-factors-associated-with-the-development-of-fibrosis-in-patients-with-nonalcoholic-fatty-liver-disease
#1
Sara Gómez de la Cuesta, Rocío Aller de la Fuente, Carla Tafur Sánchez, Olatz Izaola, Concepción García Sánchez, Natalia Mora, Jose Manuel González Hernández, Daniel de Luis Román
BACKGROUND: A prolonged non-alcoholic steatohepatitis (NASH) condition can lead to advanced stages of liver disease and the development of hepatocellular carcinoma. AIM: To evaluate analytical, anthropometric and dietary factors associated with the presence of fibrosis as this is the factor that most influences survival and evolution. METHODS: Seventy-six patients with liver biopsy-diagnosed non-alcoholic fatty liver disease (NAFLD) were included...
January 17, 2018: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/29329986/prospects-in-non-invasive-assessment-of-liver-fibrosis-liquid-biopsy-as-the-future-gold-standard
#2
REVIEW
Joeri Lambrecht, Stefaan Verhulst, Inge Mannaerts, Hendrik Reynaert, Leo A van Grunsven
Liver fibrosis is the result of persistent liver injury, and is characterized by sustained scar formation and disruption of the normal liver architecture. The extent of fibrosis is considered as an important prognostic factor for the patient outcome, as an absence of (early) treatment can lead to the development of liver cirrhosis and hepatocellular carcinoma. Till date, the most sensitive and specific way for the diagnosis and staging of liver fibrosis remains liver biopsy, an invasive diagnostic tool, which is associated with high costs and discomfort for the patient...
January 9, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29326816/immune-checkpoint-inhibition-prospects-for-prevention-and-therapy-of-hepatocellular-carcinoma
#3
REVIEW
Caryn L Elsegood, Janina Ee Tirnitz-Parker, John K Olynyk, George Ct Yeoh
The global prevalence of liver cancer is rapidly rising, mostly as a result of the amplified incidence rates of viral hepatitis, alcohol abuse and obesity in recent decades. Treatment options for liver cancer are remarkably limited with sorafenib being the gold standard for advanced, unresectable hepatocellular carcinoma but offering extremely limited improvement of survival time. The immune system is now recognised as a key regulator of cancer development through its ability to protect against infection and chronic inflammation, which promote cancer development, and eliminate tumour cells when present...
November 2017: Clinical & Translational Immunology
https://www.readbyqxmd.com/read/29312973/critical-appraisal-of-chinese-2017-guideline-on-the-management-of-hepatocellular-carcinoma
#4
REVIEW
Di-Yang Xie, Zheng-Gang Ren, Jian Zhou, Jia Fan, Qiang Gao
Hepatocellular carcinoma (HCC) is the fourth most common and the third most lethal cancer in China. An updated version of consensus-based recommendations on the management of HCC has been recently published by a multidisciplinary group of Chinese experts including liver surgeons, hepatic oncologists, radiologists and pathologists. Major changes have been made to the diagnostic criteria. In addition to dynamic multi-detector computed tomography (CT) and magnetic resonance imaging (MRI), gadoxetic acid-enhanced MRI and contrast-enhanced ultrasound (CEUS) are added to the diagnostic imaging tests...
December 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/29311396/prognostic-ability-of-bclc-b-subclassification-in-patients-with-hepatocellular-carcinoma-undergoing-transarterial-chemoembolization
#5
Marco Biolato, Giulia Gallusi, Massimo Iavarone, Giuseppe Cabibbo, Simona Racco, Adriano De Santis, Cristina Della Corte, Marcello Maida, Adolfo Francesco Attili, Angelo Sangiovanni, Calogero Cammà, Giuseppe La Torre, Antonio Gasbarrini, Antonio Grieco
Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Background and aims. A subclassification system for intermediate hepatocellular carcinoma (HCC) was recently proposed to optimize treatment allocation. The aim of this study was to assess the prognostic ability of that substaging proposal. PATIENTS AND METHODS: This is a retrospective multicenter cohort study including patients with intermediate HCC treated with transarterial chemoembolization (TACE)...
December 27, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/29301497/evaluating-screening-approaches-for-hepatocellular-carcinoma-in-a-cohort-of-hcv-related-cirrhosis-patients-from-the-veteran-s-affairs-health-care-system
#6
Nabihah Tayob, Peter Richardson, Donna L White, Xiaoying Yu, Jessica A Davila, Fasiha Kanwal, Ziding Feng, Hashem B El-Serag
BACKGROUND: Hepatocellular carcinoma (HCC) has limited treatment options in patients with advanced stage disease and early detection of HCC through surveillance programs is a key component towards reducing mortality. The current practice guidelines recommend that high-risk cirrhosis patients are screened every six months with ultrasonography but these are done in local hospitals with variable quality leading to disagreement about the benefit of HCC surveillance. The well-established diagnostic biomarker α-Fetoprotein (AFP) is used widely in screening but the reported performance varies widely across studies...
January 4, 2018: BMC Medical Research Methodology
https://www.readbyqxmd.com/read/29290957/prognostic-nomogram-for-hepatocellular-carcinoma-in-adolescent-and-young-adult-patients-after-hepatectomy
#7
Wei Zhang, Yifei Tan, Shu Shen, Li Jiang, Lunan Yan, Jiayin Yang, Bo Li, Tianfu Wen, Yong Zeng, Wen Tao Wang, Mingqing Xu
Background: Hepatocellular carcinoma (HCC) was rarely discussed in adolescent and young adult (AYA) patients. This study aimed to discuss the character of AYA HCC patients and establish an effective prognostic nomogram for patients after hepatectomy. Results: For all of the patients, the median OS was 57 months with 5-year OS rate 60.4%, and DFS was 48 months with 5-year DFS rate 51.4%. The tumor size, vascular invasion status and the pathological differentiation were the independent predictors for both OS and DFS...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29290780/fibrinogen-and-c-reactive-protein-score-is-a-prognostic-index-for-patients-with-hepatocellular-carcinoma-undergoing-curative-resection-a-prognostic-nomogram-study
#8
Wei Gan, Yong Yi, Yipeng Fu, Jinlong Huang, Zhufeng Lu, Chuyu Jing, Jia Fan, Jian Zhou, Shuangjian Qiu
Background: While curative resection is the established strategy for Hepatocellular carcinoma (HCC) patients, the prognosis still remains poor, and the efficiency of existing prediction models is unsatisfactory. Therefore, we aimed to develop a credible and easy-to-use prognostic index for patients with HCC undergoing curative therapy. Methods: A total of 768 patients with HCC, who underwent curative resection from December 2010 to June 2012 in Zhongshan Hospital, were divided into a training cohort with 616 patients and a validating cohort of 152 patients at a ratio of 4 to 1 by random allocation...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29277961/liver-resection-of-hepatocellular-carcinoma-in-patients-with-portal-hypertension-and-multiple-tumors
#9
Takao Ohkubo, Yutaka Midorikawa, Hisashi Nakayama, Masamichi Moriguchi, Osamu Aramaki, Shintaro Yamazaki, Tokio Higaki, Tadatoshi Takayama
AIM: Liver resection for hepatocellular carcinoma (HCC) has been recommended only for patients with a single tumor without portal hypertension. We aimed to validate this treatment strategy that is based on by the Barcelona Clinic Liver Cancer staging system. METHODS: Patients undergoing liver resection were divided into two groups: patients with single HCC without portal hypertension (Group 1) and those with at least one factors of portal hypertension and multiple tumors up to three lesions each ≤ 3 cm (Group 2)...
December 26, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29276410/clinical-course-of-nonalcoholic-fatty-liver-disease-an-assessment-of-severity-progression-and-outcomes
#10
Jason C Simeone, Jay P Bae, Byron J Hoogwerf, Qian Li, Axel Haupt, Ayad K Ali, Marilyn K Boardman, Beth L Nordstrom
Purpose: To identify the characteristics and initial disease severity of patients with nonalcoholic fatty liver disease (NAFLD) and assess incidence and risk factors for disease progression in a retrospective study. Methods: Patients ≥18 years of age without alcoholism or other liver diseases (eg, hepatitis B/C) were selected from Geisinger Health System electronic medical record data from 2004 to 2015. Initial disease stage was stratified into uncomplicated NAFLD, advanced fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver transplant using clinical biomarkers, diagnosis, and procedure codes...
2017: Clinical Epidemiology
https://www.readbyqxmd.com/read/29273376/validation-of-the-american-joint-committee-on-cancer-eighth-edition-staging-system-in-patients-undergoing-hepatectomy-for-hepatocellular-carcinoma-a-us-population-based-study
#11
Guoqing Zhang, Renfeng Li, Xiaoyang Zhao, Songfeng Meng, Jianwen Ye, Longshuan Zhao
BACKGROUND: The American Joint Committee on Cancer (AJCC) eighth edition staging system for hepatocellular carcinoma (HCC) has incorporated several significant changes. This study aims to evaluate the newly proposed staging system and assess its strengths and weaknesses. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results database, we identified patients with pathologically confirmed stage I-III HCC diagnosed between 2004 and 2014. RESULTS: After all exclusion criteria were applied, AJCC seventh and eighth edition staging was possible in 4931 patients...
February 2018: Journal of Surgical Research
https://www.readbyqxmd.com/read/29258507/prognostic-significance-of-microvascular-invasion-in-tumor-stage-for-hepatocellular-carcinoma
#12
Yong Keun Park, Sung Kyu Song, Bong-Wan Kim, Seung-Keun Park, Chul-Woon Chung, Hee-Jung Wang
BACKGROUND: The presence of microvascular invasion (McVI) in hepatocellular carcinoma (HCC) has been proposed as a cause of recurrence and poor survival, although this has not been officially emphasized in staging systems. Thus, we conducted a retrospective study to investigate the prognostic importance of McVI in tumor staging in patients with HCC who underwent hepatic resection. METHODS: A retrospective analysis was performed of patients who underwent hepatic resection for HCC at our center from 1994 to 2012...
December 19, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29249005/metronomic-capecitabine-as-second-line-treatment-for-hepatocellular-carcinoma-after-sorafenib-discontinuation
#13
Franco Trevisani, Giovanni Brandi, Francesca Garuti, Maria Aurelia Barbera, Raffaella Tortora, Andrea Casadei Gardini, Alessandro Granito, Francesco Tovoli, Stefania De Lorenzo, Andrea Lorenzo Inghilesi, Francesco Giuseppe Foschi, Mauro Bernardi, Fabio Marra, Rodolfo Sacco, Giovan Giuseppe Di Costanzo
PURPOSE: Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC). METHODS: 117 patients undergoing MC were compared to 112 patients, eligible for this treatment, but undergoing best supportive care (BSC) after sorafenib discontinuation for toxicity or HCC progression. The two groups were compared for demographic and clinical features...
December 16, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29246702/nomogram-to-predict-survival-of-patients-with-recurrence-of-hepatocellular-carcinoma-after-surgery
#14
Wei He, Baogang Peng, Yunqiang Tang, Junpin Yang, Yun Zheng, Jiliang Qiu, Ruhai Zou, Jingxian Shen, Binkui Li, Yunfei Yuan
BACKGROUND & AIMS: We aimed to establish and validate a nomogram to predict survival at 2 and 5 years after recurrence of hepatocellular carcinoma (HCC) in patients who have undergone curative resection. METHODS: We developed a nomogram using data from a training cohort of 638 patients (most with hepatitis B virus infection) with recurrence of HCC after curative resection at Sun Yat-sen University Cancer Center, in Guangzhou, China from 2007 through 2013. The median follow-up time was 39...
December 12, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29234636/validation-and-potential-of-albumin-bilirubin-grade-and-prognostication-in-a-nationwide-survey-of-46-681-hepatocellular-carcinoma-patients-in-japan-the-need-for-a-more-detailed-evaluation-of-hepatic-function
#15
Atsushi Hiraoka, Kojiro Michitaka, Takashi Kumada, Namiki Izumi, Masumi Kadoya, Norihiro Kokudo, Shoji Kubo, Yutaka Matsuyama, Osamu Nakashima, Michiie Sakamoto, Tadatoshi Takayama, Takashi Kokudo, Kosuke Kashiwabara, Masatoshi Kudo
Background/Aim: Recently, albumin-bilirubin (ALBI) scoring/grading, consisting of only albumin and total bilirubin, has been proposed. We examined the efficacy of this grading system for determining hepatic function in patients with hepatocellular carcinoma (HCC). Methods/Materials: The prognoses of 46,681 HCC patients based on results obtained from a nationwide survey conducted in Japan from 2001 to 2007 were evaluated using (1) Japan Integrated Staging (JIS), consisting of Child-Pugh classification and TNM staging (TNM), (2) modified JIS (m-JIS), consisting of liver damage grading and TNM, and (3) ALBI-TNM (ALBI-T), consisting of ALBI grading and TNM, and the results were compared...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29234628/adoption-of-sorafenib-for-the-treatment-of-advanced-stage-hepatocellular-carcinoma-in-oncology-practices-in-the-united-states
#16
Helen M Parsons, Quyen Chu, Jordan J Karlitz, Jennifer L Stevens, Linda C Harlan
Background: The adoption of sorafenib into oncology practice as a first-line systemic treatment for advanced hepatocellular carcinoma (HCC) is not well understood. We examined sorafenib use since Food and Drug Administration (FDA) approval in 2007 and associated survival for individuals diagnosed with advanced HCC, conducting a population-based evaluation of treatment patterns and outcomes for this newly approved drug in the US over time. Methods: We identified individuals diagnosed with Barcelona Clinic Liver Cancer Stage C from the 2007 and 2012 National Cancer Institute Patterns of Care study...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/29231047/cost-effectiveness-analysis-of-treatments-involving-radioembolization-in-intermediate-stage-hepatocellular-carcinoma
#17
Carla Rognoni, Oriana Ciani, Silvia Sommariva, Rosanna Tarricone
AIM: We evaluated two treatment sequences, transarterial radioembolization followed by transarterial chemoembolization and possibly sorafenib (=TTS) versus transarterial radioembolization followed by sorafenib alone (=TS), to identify the most cost-effective pathway to treat intermediate-stage hepatocellular carcinoma from the Italian healthcare system perspective. MATERIALS & METHODS: A Markov model was developed to project costs and health outcomes for TTS and TS over a lifetime horizon...
December 12, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29221172/the-prognostic-value-of-inflammation-based-scores-in-advanced-hepatocellular-carcinoma-patients-prior-to-treatment-with-sorafenib
#18
Guillaume Conroy, Julia Salleron, Arthur Belle, Mouni Bensenane, Abdelbasset Nani, Ahmet Ayav, Didier Peiffert, Anthony Lopez, Cédric Baumann, Hélène Barraud, Jean-Pierre Bronowicki
Background and Aims: The multikinase inhibitor sorafenib is the only currently approved drug for the indication of advanced hepatocellular carcinoma (HCC). It provides a limited gain in survival time but is frequently associated with adverse events. We currently lack simple prognostic factors in sorafenib-treated HCC patients. Various inflammation-based scores (IBSs) have been evaluated as predictors of tumor recurrence and survival in various malignancies (including HCC). The objective of the present study was to determine the prognostic value of IBSs for overall survival (OS) in advanced HCC patients prior to the initiation of sorafenib therapy...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29194711/institutional-decision-to-adopt-y90-as-primary-treatment-for-hcc-informed-by-a-1-000-patient-15-year-experience
#19
Riad Salem, Ahmed Gabr, Ahsun Riaz, Ronald Mora, Rehan Ali, Michael Abecassis, Ryan Hickey, Laura Kulik, Daniel Ganger, Steven Flamm, Rohi Atassi, Bassel Atassi, Kent Sato, Al B Benson, Mary F Mulcahy, Nadine Abouchaleh, Ali Al Asadi, Kush Desai, Bartley Thornburg, Michael Vouche, Ali Habib, Juan Caicedo, Frank H Miller, Vahid Yaghmai, Joseph R Kallini, Samdeep Mouli, Robert J Lewandowski
Y90 transarterial radioembolization (TARE) is a transarterial locoregional therapy (LRT) for hepatocellular carcinoma (HCC). In this study, we present overall survival outcomes (OS) in a 1000-patient cohort acquired over a 15-year period. Between December 1, 2003 and March 31, 2017, 1000 patients with HCC were treated with TARE as part of a prospective cohort study. A comprehensive review of toxicity and survival outcomes was performed. Outcomes were stratified by baseline Child-Pugh (CP) class, United Network for Organ Sharing (UNOS) and Barcelona Clinic Liver Cancer (BCLC) staging systems...
December 1, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29181069/sorafenib-combined-with-hepatectomy-in-patients-with-intermediate-stage-and-advanced-hepatocellular-carcinoma
#20
Lei Zhuang, Tianfu Wen, Mingqing Xu, Jiayin Yang, Wentao Wang, Hong Wu, Yong Zeng, Lvnan Yan, Yonggang Wei, Bo Li
Introduction: Guidelines based on the Barcelona Clinic Liver Cancer (BCLC) classification system recommend that hepatic resection should be performed only in patients in BCLC stage A. Patients with stage B or stage C should receive palliative or no treatment. However, actual clinical practice varies, and a recent analysis of hepatocellular carcinoma (HCC) surgery outcomes in high volume surgical centers throughout the world concluded that hepatectomy can provide survival benefit for selected patients in all three BCLC stages...
October 2017: Archives of Medical Science: AMS
keyword
keyword
66281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"